Recombinant DcR3 Polypeptide for Spinal Cord Injury Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for spinal cord injuries are limited, with no effective cure for severe injuries, and existing methods primarily focus on early steroid administration and acute surgical intervention to minimize cord edema, offering little hope for functional recovery.
Innovation Solution
Administration of a recombinant decoy receptor 3 (DcR3) polypeptide, either alone or fused with an immunoglobulin constant region fragment, to promote healing and improve locomotor function recovery by modulating inflammatory responses and enhancing tissue repair mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dose steroids and acute surgical intervention are administered to minimize cord edema, then acute phase injury is reduced, but functional recovery and locomotor function improvement remain limited
Solution Approach 1:
The patent administers DcR3 polypeptide in the acute phase (within 24-48 hours of injury) before secondary injury cascades fully develop, preventing inflammatory damage before it occurs rather than treating it after. This preliminary intervention blocks TNF-alpha and other cytokine-mediated pathways that would otherwise lead to neuronal death and functional loss.
Solution Approach 2:
DcR3 acts as a soluble decoy receptor that intermediates between inflammatory cytokines (TNF-alpha, LIF, IL-6) and their cell surface receptors. By binding these cytokines in circulation and at the injury site, DcR3 prevents them from activating harmful inflammatory pathways while allowing the body's natural healing processes to proceed.
2Ease of operation
If current standard treatments are used, then acute symptoms are managed, but severe spinal cord injuries remain incurable with no effective cure
Solution Approach 1:
The patent changes the therapeutic parameter from mechanical/surgical intervention to biochemical modulation by administering recombinant DcR3 polypeptide. This molecular therapy targets the underlying inflammatory and apoptotic pathways that drive secondary injury, fundamentally altering the treatment approach from symptom management to disease modification.
Solution Approach 2:
The invention uses a fusion protein combining DcR3 with Fc region of immunoglobulin, creating a composite molecule that enhances pharmacokinetic properties, prolongs circulation half-life, and improves delivery to the injury site while maintaining cytokine-binding functionality.
3Loss of time
If early intervention is provided, then cord edema is minimized, but the opportunity for later functional recovery is lost
Solution Approach 1:
The patent establishes continuous therapeutic action by administering DcR3 at multiple time points (acute phase within 24-48 hours, and subacute phase up to 7-14 days), maintaining anti-inflammatory and neuroprotective effects throughout the critical recovery window. This continuous presence of DcR3 bridges the gap between acute stabilization and long-term rehabilitation.
Solution Approach 2:
The treatment protocol employs periodic administration of DcR3 polypeptide at scheduled intervals (daily or every other day for 5-14 days), providing rhythmic anti-inflammatory coverage that matches the wave-like nature of inflammatory responses and promotes sustained neuronal survival and functional recovery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DcR3 treatment demonstrates improved hindlimb functional recovery, reduces wound cavity sizes, increases myelin sparing, and promotes anti-inflammatory cytokine expression and angiogenesis at lesion sites, suggesting potential for enhanced spinal cord injury recovery.
Implementation Method 1
DcR3 has been shown to bind to pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-a), leukemia inhibitory factor (LIF), and interleukin-6 (IL-6), with high affinity
Implementation Method 2
DcR3 has been shown to promote angiogenesis, the formation of new blood vessels, which is critical for tissue repair and recovery after SCI
Implementation Method 3
DcR3 treatment has been shown to increase the expression of anti-inflammatory cytokines, such as interleukin-4 (IL-4) and interleukin-10 (IL-10), while decreasing the expression of pro-inflammatory cytokines
Data Source
AI summary
Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.